S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

$0.99
-0.04 (-3.89%)
(As of 04/17/2024 ET)
Today's Range
$0.93
$1.05
50-Day Range
$0.99
$1.75
52-Week Range
$0.42
$2.05
Volume
1.22 million shs
Average Volume
1.79 million shs
Market Capitalization
$981.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Adaptimmune Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
153.3% Upside
$2.50 Price Target
Short Interest
Healthy
0.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Adaptimmune Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.44) to ($0.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars

Medical Sector

799th out of 913 stocks

Biological Products, Except Diagnostic Industry

118th out of 134 stocks

ADAP stock logo

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Stock Price History

ADAP Stock News Headlines

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.16
Biden out June 13; Kamala won’t replace him?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.29
Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 6.9%
Biden out June 13; Kamala won’t replace him?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Peter W. Sonsini's Net Worth
ADAP Sep 2024 2.500 put
Adaptimmune Therapeutics Earnings Preview
Adaptimmune Therapeutics earnings: here's what Wall Street expects
ADAP Apr 2024 1.500 put
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/17/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADAP
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$4.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+153.3%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-113,870,000.00
Net Margins
-188.90%
Pretax Margin
-186.68%

Debt

Sales & Book Value

Annual Sales
$60.28 million
Book Value
$0.04 per share

Miscellaneous

Free Float
821,518,000
Market Cap
$981.29 million
Optionable
Optionable
Beta
2.39
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives


ADAP Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" ADAP shares.
View ADAP analyst ratings
or view top-rated stocks.

What is Adaptimmune Therapeutics' stock price target for 2024?

1 analysts have issued 12 month price targets for Adaptimmune Therapeutics' shares. Their ADAP share price targets range from $1.00 to $4.00. On average, they anticipate the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 153.3% from the stock's current price.
View analysts price targets for ADAP
or view top-rated stocks among Wall Street analysts.

How have ADAP shares performed in 2024?

Adaptimmune Therapeutics' stock was trading at $0.7930 on January 1st, 2024. Since then, ADAP stock has increased by 24.5% and is now trading at $0.9870.
View the best growth stocks for 2024 here
.

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ADAP earnings forecast
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.12. The biotechnology company had revenue of $0.23 million for the quarter, compared to analyst estimates of $4.80 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 155.39% and a negative net margin of 188.90%.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?
When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (0.03%) and Columbia Advisory Partners LLC (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Garry E Menzel, Gavin Wood, John Lunger and William C Bertrand Jr.
View institutional ownership trends
.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners